

B.S.B. PHARMACY LIMITED

**Company Registration Number:
01945726 (England and Wales)**

Unaudited abridged accounts for the year ended 31 March 2021

Period of accounts

Start date: 01 April 2020

End date: 31 March 2021

B.S.B. PHARMACY LIMITED

Contents of the Financial Statements for the Period Ended 31 March 2021

Balance sheet

Notes

B.S.B. PHARMACY LIMITED

Balance sheet

As at 31 March 2021

	<i>Notes</i>	<i>2021</i>	<i>2020</i>
		£	£
Fixed assets			
Intangible assets:	3	235,625	248,302
Tangible assets:	4	65,910	83,819
Total fixed assets:		<u>301,535</u>	<u>332,121</u>
Current assets			
Stocks:		52,733	91,030
Debtors:		302,312	326,960
Cash at bank and in hand:		98,285	21,499
Total current assets:		<u>453,330</u>	<u>439,489</u>
Creditors: amounts falling due within one year:		(330,350)	(370,466)
Net current assets (liabilities):		<u>122,980</u>	<u>69,023</u>
Total assets less current liabilities:		424,515	401,144
Creditors: amounts falling due after more than one year:		(42,414)	(49,710)
Total net assets (liabilities):		<u>382,101</u>	<u>351,434</u>
Capital and reserves			
Called up share capital:		800	800
Profit and loss account:		381,301	350,634
Shareholders funds:		<u>382,101</u>	<u>351,434</u>

The notes form part of these financial statements

B.S.B. PHARMACY LIMITED

Balance sheet statements

For the year ending 31 March 2021 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company's profit & loss account.

**This report was approved by the board of directors on 07 October 2021
and signed on behalf of the board by:**

Name: M S UBHI
Status: Director

The notes form part of these financial statements

B.S.B. PHARMACY LIMITED

Notes to the Financial Statements

for the Period Ended 31 March 2021

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

Turnover policy

Revenue is measured at the fair value of the consideration received or receivable. Revenue is reduced for estimated customer rebates and other similar allowances. Revenue from the sale of goods is recognised when goods are delivered and legal title has passed.

Tangible fixed assets and depreciation policy

Tangible fixed assets held for company's own use are stated at cost less accumulated depreciation and accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost, less estimated residual value, of each asset on reducing value basis over its expected useful lives on a straight line basis at rates of 3-20% per annum. At each balance sheet date, the company reviews the carrying amount of its tangible fixed assets to determine whether there is any indication that any items have suffered an impairment loss and makes the necessary adjustment to account for the impairment.

Valuation and information policy

Stocks are valued at lower of cost and net realisable value, after making due allowance for obsolete and slow moving items. Cost includes all direct expenditure and an appropriate proportion of fixed and variable overheads. When stocks are sold, the carrying amount of those stocks is recognised as an expense in the period in which the related revenue is recognised.

Other accounting policies

Taxation represents the sum of tax currently payable and deferred tax. The company's liability for current tax is calculated using rates that have been enacted or substantively enacted by the end of the reporting period. Deferred tax is recognised on all timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax basis used in the computation of taxable profit.

B.S.B. PHARMACY LIMITED

Notes to the Financial Statements for the Period Ended 31 March 2021

2. Employees

	<i>2021</i>	<i>2020</i>
Average number of employees during the period	4	4

B.S.B. PHARMACY LIMITED

Notes to the Financial Statements for the Period Ended 31 March 2021

3. Intangible Assets

	Total
Cost	£
At 01 April 2020	316,934
At 31 March 2021	<u>316,934</u>
Amortisation	
At 01 April 2020	68,632
Charge for year	12,677
At 31 March 2021	<u>81,309</u>
Net book value	
At 31 March 2021	<u><u>235,625</u></u>
At 31 March 2020	<u><u>248,302</u></u>

B.S.B. PHARMACY LIMITED

Notes to the Financial Statements **for the Period Ended 31 March 2021**

4. Tangible Assets

	Total
Cost	£
At 01 April 2020	196,619
At 31 March 2021	<u>196,619</u>
Depreciation	
At 01 April 2020	112,800
Charge for year	17,909
At 31 March 2021	<u>130,709</u>
Net book value	
At 31 March 2021	<u><u>65,910</u></u>
At 31 March 2020	<u><u>83,819</u></u>

B.S.B. PHARMACY LIMITED

Notes to the Financial Statements

for the Period Ended 31 March 2021

5. Related party transactions

Name of the related party:	Ubhi Pharmacy Limited
Relationship:	Holding Company
Description of the Transaction:	Balance on the current account between the two companies. The holding company provides management services to the company.
	£
Balance at 01 April 2020	82,219
Balance at 31 March 2021	60,552

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.